Wegovy and Zepbound show higher efficacy, but pricing and coverage can be tougher, so plan choice should balance results, budget, and dosing preference with a clinician
The C1831 device category was made effective in the OPPS on October 1, 2021, and expired on September 30, 2024, as such, we cannot reinstate the pass-through payment status of C1831 because reinstatement would make the pass-through payment status effective longer than the maximum 3-year period permitted under section 1833(t)(6)(B)(iii) of the Act and 419.66(g)
Dermatan sulfate and chondroitin sulfate production increases
Yes, Nutricost Glutathione is considered one of the best glutathione supplements in Bangladesh due to its purity, dosage, and value
For additional products in metabolic or cardiovascular diseases, Ascendis is eligible for up to US$77.5m in milestone payments, plus royalties